|
|
68Ga-FAPI在乳腺癌诊断中的研究进展
|
Abstract:
乳腺癌(Breast cancer, BC)是女性最常见的恶性肿瘤，又称为“粉红杀手”，在癌症相关妇女死亡原因中排第二。成纤维细胞活化蛋白(fibroblast activation protein, FAP)，高度表达于肿瘤相关成纤维细胞中，近年来，基于喹啉设计的小分子FAP抑制剂(FAP inhibitor, FAPI)显示出优秀的FAP亲和力，在乳腺癌中摄取量较高。随着技术的发展，68Ga标记的FAPI在乳腺癌的诊断中得到了进一步的发展。本文就近年来68Ga-FAPI在乳腺癌中的临床研究和应用进展做简要综述，以提高其临床应用效益。
Breast cancer (BC) is the most common malignancy in women, also known as the “Pink Killer”. BC is the second leading cause of cancer-related death in women. Fibroblast activation protein (FAP) is highly expressed in tumor-associated fibroblasts. Recently, small molecule FAP inhibitor (FAPI) based on quinoline design has shown an excellent affinity for FAP, high intake in breast cancer. With the development of technology, 68Ga-labeled FAPI (68Ga-FAPI) has been further developed in the diagnosis of breast cancer. In this review, the clinical research and application of 68Ga-FAPI in breast cancer were reviewed to improve the clinical benefit.
| [1] | 杨一风, 祁章璇, 聂生东. 基于多模态MRI与深度学习的乳腺病变良恶性鉴别[J]. 波谱学杂志, 2022, 39(4): 401-412. |
| [2] | Weaver, O. and Leung, J.W.T. (2018) Biomarkers and Imaging of Breast Cancer. American Journal of Roentgenolog, 210, 271-278. https://doi.org/10.2214/AJR.17.18708 |
| [3] | Yang, B., Ren, G., Song, E., et al. (2020) Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Sur-vey of 110 Hospitals. Oncologist, 25, e1473-e1480.
https://doi.org/10.1634/theoncologist.2020-0001 |
| [4] | Hyuna, S. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [5] | 乳腺癌诊疗指南(2022年版) [J]. 中国合理用药探索, 2022, 19(10): 1-26. |
| [6] | 张富强, 李强, 杨辉. 氟-18脱氧葡萄糖正电子发射断层显像对乳腺良恶性病变的鉴别诊断价值[J]. 慢性病学杂志, 2022, 23(5): 788-90. |
| [7] | Hamson, E.J., Keane, F.M., Tholen, S., et al. (2014) Understanding Fibroblast Activation Protein (FAP): Substrates, Activities, Expression and Targeting for Cancer Therapy. Proteomics—Clinical Applications, 8, 454-463.
https://doi.org/10.1002/prca.201300095 |
| [8] | Fitzgerald, A.A. and Weiner, L.M. (2020) The Role of Fibroblast Ac-tivation Protein in Health and Malignancy. Cancer and Metastasis Reviews, 39, 783-803. https://doi.org/10.1007/s10555-020-09909-3 |
| [9] | 陈跃, 邱琳, 石洪成, 等. 68Ga-成纤维细胞激活蛋白抑制剂PET/CT显像指南[J]. 中国医学影像技术, 2022, 38(6): 801-806. |
| [10] | K？mek, H., Can, C., Güzel, Y., et al. (2021) 68Ga-FAPI-04 PET/CT, a New Step in Breast Cancer Imaging: A Comparative Pilot Study with the 18F-FDG PET/CT. Annals of Nuclear Medicine, 35, 744-752.
https://doi.org/10.1007/s12149-021-01616-5 |
| [11] | Loktev, A., Lindner, T., Mier, W., et al. (2018) A Tu-mor-Imaging Method Targeting Cancer-Associated Fibroblasts. Journal of Nuclear Medicine, 59, 1423-1429. https://doi.org/10.2967/jnumed.118.210435 |
| [12] | Eshet, Y., Tau, N., Levanon, K., et al. (2023) The Role of 68 Ga-FAPI PET/CT in Breast Cancer Response Assessment and Follow-Up. Clinical Nuclear Medicine, 48, 685-688. https://doi.org/10.1097/RLU.0000000000004744 |
| [13] | 刘馨, 伍治平, 王熙才. 乳腺癌相关成纤维细胞与成纤维活化蛋白[J]. 肿瘤防治研究, 2013, 40(7): 717-719. |
| [14] | 孙朝晖, 邹立伟, 杨凌. 成纤维细胞活化蛋白的研究进展[J]. 生物化学与生物物理进展, 2020, 47(1): 39-52. |
| [15] | Chen, H., Zhao, L., Ruan, D., et al. (2021) Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in Patients Presenting with Inconclusive [18F]FDG PET/CT Findings. European Journal of Nuclear Medicine and Molecular Imaging, 48, 73-86. https://doi.org/10.1007/s00259-020-04940-6 |
| [16] | 叶雨萌, 周学素, 田启威, 等. 成纤维细胞活化蛋白抑制剂在肿瘤诊疗中的研究进展[J]. 上海师范大学学报(自然科学版), 2022, 51(4): 436-442. |
| [17] | Xu, W., Meng, T., Shang, Q., et al. (2022) Uncommon Metastases from Occult Breast Cancer Revealed by 18F-FDG and 68Ga-FAPI PET/CT. Clinical Nuclear Medicine, 47, 751-753. https://doi.org/10.1097/RLU.0000000000004193 |
| [18] | 《中国肿瘤临床》文章推荐: 乳腺癌前哨淋巴结活检规范化操作指南(2022精要版) [J]. 中国肿瘤临床, 2023, 50(1): 36. |
| [19] | Shen, S., Zhou, Y., Xu, Y., et al. (2015) A Multi-Centre Randomised Trial Comparing Ultrasound vs Mammography for Screening Breast Cancer in High-Risk Chinese Women. British Journal of Cancer, 112, 998-1004.
https://doi.org/10.1038/bjc.2015.33 |
| [20] | 孙艺宁, 陈兰. 非肿块型乳腺病变超声诊断新进展[J]. 中国现代医生, 2023, 61(1): 134-137. |
| [21] | Li, W., Newitt, D.C., Gibbs, J., et al. (2020) Predicting Breast Cancer Response to Neoad-juvant Treatment Using Multi-Feature MRI: Results from the I-SPY 2 TRIAL. NPJ Breast Cancer, 6, Article No. 63.
https://doi.org/10.1038/s41523-020-00203-7 |
| [22] | Liu, H., Chen, Y., Zhang, Y., et al. (2021) A Deep Learning Model Integrating Mammography and Clinical Factors Facilitates the Malignancy Prediction of BI-RADS 4 Microcalci-fications in Breast Cancer Screening. European Radiology, 31, 5902-5912. https://doi.org/10.1007/s00330-020-07659-y |
| [23] | Groheux, D. and Hindie, E. (2021) Breast Cancer: Initial Workup and Staging with FDG PET/CT. Clinical and Translational Imaging, 9, 221-231. https://doi.org/10.1007/s40336-021-00426-z |
| [24] | Backhaus, P., Burg, M.C., Roll, W., et al. (2022) Simultaneous FAPI PET/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer. Radiology, 302, 39-47. https://doi.org/10.1148/radiol.2021204677 |
| [25] | Elboga, U., Sahin, E., Kus, T., et al. (2021) Superiority of 68Ga-FAPI PET/CT Scan in Detecting Additional Lesions Compared to 18FDG PET/CT Scan in Breast Cancer. Annals of Nuclear Medicine, 35, 1321-1331.
https://doi.org/10.1007/s12149-021-01672-x |
| [26] | Korol, P., Samokhin, A., Shcherbina, O.B. and Пономаренко, H.М. (2019) FAPI-PET/CT: A New Direction for Diagnostic Imaging In Nuclear Medicine. Radiation Diagnostics Ra-diation Therapy, 4, 48-54.
https://doi.org/10.37336/2707-0700-2019-4-5 |
| [27] | Dendl, K., Koerber, S.A., Watabe, T., et al. (2023) Current Sta-tus of Fibroblast Activation Protein Imaging in Gynecologic Malignancy and Breast Cancer. PET Clinics, 18, 345-351. https://doi.org/10.1016/j.cpet.2023.03.005 |
| [28] | Zheng, S., Lin, J., Zhu, Y., et al. (2023) 68Ga-FAPI versus 18F-FDG PET/CT in Evaluating Newly Diagnosed Breast Cancer Patients: A Head-to-Head Comparative Study. Clinical Nuclear Medicine, 48, e104-e109.
https://doi.org/10.1097/RLU.0000000000004523 |
| [29] | Ballal, S., Yadav, M.P., Moon, E.S., et al. (2021) Biodis-tribution, Pharmacokinetics, Dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the Head-to-Head Comparison with [18F]F-FDG PET/CT in Patients with Various Cancers. European Journal of Nuclear Medicine and Molecular Imaging, 48, 1915-1931. https://doi.org/10.1007/s00259-020-05132-y |
| [30] | Elboga, U. (2021) Superiority of 68Ga-FAPI PET/CT Scan in Detecting Additional Lesions Compared to 18FDG PET/CT Scan in Breast Cancer. Annals of Nuclear Medicine, 35, 1321-1331. https://doi.org/10.1007/s12149-021-01672-x |
| [31] | Komek, H. (2021) 68Ga-FAPI-04 PET/CT, a New Step in Breast Cancer Imaging: A Comparative Pilot Study with the 18F-FDG PET/CT. Annals of Nu-clear Medicine, 35, 744-752. https://doi.org/10.1007/s12149-021-01616-5 |
| [32] | Qiu, S., Zou, S., Cheng, S., et al. (2022) Positive FAPI PET/CT in a Bilateral Mammary Angiosarcoma Patient with Less Impressive FDG PET/CT Imag-es. Clinical Nuclear Medicine, 47, 648-650.
https://doi.org/10.1097/RLU.0000000000004089 |
| [33] | Dendl, K. (2021) 68Ga-FAPI-PET/CT in Patients with Var-ious Gynecological Malignancies. European Journal of Nuclear Medicine and Molecular Imaging, 48, 4089-4100. https://doi.org/10.1007/s00259-021-05378-0 |
| [34] | Taralli, S., Lorusso, M., Perrone, E., et al. (2023) PET/CT with Fibroblast Activation Protein Inhibitors in Breast Cancer: Diagnostic and Theranostic Application—A Literature Review. Cancers, 15, Article 908.
https://doi.org/10.3390/cancers15030908 |
| [35] | Xu, T., Wang, W., Yang, C., et al. (2022) 68Ga-DOTA-FAPI-04 Uptake of Accessory Breast in a Patient with Breast Cancer. Clinical Nuclear Medicine, 47, 564-565. https://doi.org/10.1097/RLU.0000000000004069 |
| [36] | Park, M., Kim, D., Ko, S., et al. (2022) Breast Cancer Me-tastasis: Mechanisms and Therapeutic Implications. International Journal of Molecular Sciences, 23, Article 6806. https://doi.org/10.3390/ijms23126806 |
| [37] | Li, T., Jiang, X., Zhang, Z., et al. (2022) Case Report: 68Ga-FAPI PET/CT, a More Advantageous Detection Mean of Gastric, Peritoneal, and Ovarian Metastases from Breast Cancer. Frontiers in Oncology, 12, Article 1013066.
https://doi.org/10.3389/fonc.2022.1013066 |
| [38] | Sousaris, N., Mendelsohn, G. and Barr, R.G. (2013) Lung Cancer Metastatic to Breast: Case Report and Review of the Literature. Ultrasound Quarterly, 29, 205-209. https://doi.org/10.1097/RUQ.0b013e3182a00fc4 |
| [39] | Hosonaga, M., Saya, H. and Arima, Y. (2020) Molecular and Cellular Mechanisms Underlying Brain Metastasis of Breast Cancer. Cancer and Metastasis Reviews, 39, 711-720. https://doi.org/10.1007/s10555-020-09881-y |
| [40] | Tahara, R.K., Brewer, T.M., Theriault, R.L. and Ueno, N.T. (2019) Bone Metastasis of Breast Cancer. In: Ahmad, A., Ed., Breast Cancer Metastasis and Drug Resistance, Springer, Cham, 105-129.
https://doi.org/10.1007/978-3-030-20301-6_7 |
| [41] | Lind, K., Borhani-Khomani, K., Okholm, M., et al. (2022) Rou-tine X-Ray of the Chest Is Not Justified in Staging of Patients with Primary Breast Cancer. Danish Medical Journal, 69, A06220380. |
| [42] | Magnoni, F., Di Tonno, C., Accardo, G., et al. (2019) Breast Cancer with Rare Metastatic Manifesta-tion. Future Oncology, 15, 2437-2340. https://doi.org/10.2217/fon-2019-0263 |
| [43] | Simanek, M. and Koranda, P. (2016) SPECT/CT Imaging in Breast Cancer—Current Status and Challenges. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic, 160, 474-483.
https://doi.org/10.5507/bp.2016.036 |
| [44] | Wang, Q., Tang, W., Cai, L. and Chen, Y. (2022) Non-18F-FDG-Avid Intrahepatic Metastasis of Breast Cancer Revealed by 68Ga-FAPI PET/CT. Clinical Nuclear Medicine, 47, 228-230.
https://doi.org/10.1097/RLU.0000000000003905 |
| [45] | Hathi, D.K. and Jones, E.F. (2019) 68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. Radiology: Imaging Cancer, 1, e194003. https://doi.org/10.1148/rycan.2019194003 |
| [46] | Laura, G. (2023) FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma. Biomedicines, 11, Article 1350. https://doi.org/10.3390/biomedicines11051350 |
| [47] | Eshet, Y., Tau, N., Apter, S., et al. (2023) The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer. Clinical Nuclear Medicine, 48, 228-232. https://doi.org/10.1097/RLU.0000000000004540 |
| [48] | Masatoshi, H. (2023) Non-Oncologic Incidental Uptake on FAPI PET/CT Imaging. The British Journal of Radiology, 96, Article ID: 20220463. https://doi.org/10.1259/bjr.20220463 |
| [49] | Ding, F., Huang, C., Liang, C., et al. (2021) 68Ga-FAPI-04 vs. 18F-FDG in a Longitudinal Preclinical PET Imaging of Metastatic Breast Cancer. European Journal of Nuclear Medicine and Mo-lecular Imaging, 49, 290-300.
https://doi.org/10.1007/s00259-021-05442-9 |
| [50] | Shang, Q., Hao, B., Xu, W., et al. (2022) 68Ga-FAPI PET/CT Detected Non-FDG-Avid Bone Metastases in Breast Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 49, 2096-2097.
https://doi.org/10.1007/s00259-021-05664-x |
